The project that prompted the formation of Serodus AS is no longer the driving force of this start-up company. But the founding research did spark a deal that brought the firm a similar but more advanced asset, now one of three the firm is developing for cardiovascular indications ranging from high systolic blood pressure to atrial fibrillation to heart failure. Serodus in-licensed its lead candidate, a peptide classified as an opioid receptor agonist from Zealand Pharma, which took the compound through several clinical trials in both acute and chronic heart failure. Serodus thinks it could potentially develop a 5-HT-4 receptor antagonist it calls SER102 for atrial fibrillation that occurs in connection with surgery.
Gaustadalléen 21
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the coverage topics, content format or the method in which you receive and access Scrip, or if you love it how it is, now is the time to have your voice heard.
CEO Paul Stoffels said gaining US clearance for an IND for its novel CAR-T product was demanding, but now opens up a pathway towards a pivotal study starting in 2025.
A final rejection of Leqembi could also spell the same fate for Lilly’s rival drug but public outcry and demand for Alzheimer’s therapies might force the regulator’s hand
GSK is sticking to its guns on its forecasts for Blenrep and the firm’s total sales in 2031 despite concerns about the antibody-drug conjugate’s approvability in the US.
The highlights of recent comments and insights from industry executives on the key issues covered in Scrip.
Cipla’s partnered filgrastim biosimilar is expected to debut in the US in Q2 FY26 and the Indian firm expects an investment return ratio for its biosimilar engine “not too far” from that of a complex generic product amid an enabling regulatory environment.
